title: HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis.
abstract: OBJECTIVE
  Human epidermal growth factor receptor (HER) family plays an important role in gastric cancer (GC), especially HER2. Too much attention has been paid to HER2; however, the functions of HER3 and HER4 overexpression in GC are always ignored. The clinicopathological and prognostic roles of HER3 and HER4 in GC are controversial. In this study, a systematic review and meta-analysis was conducted to evaluate the use of HER3 or HER4 as a predictor of clinicopathology and survival time in GC patients.
  
  
  METHODS
  Eligible studies were searched on PubMed, Ovid, Web of Science, and Cochrane databases through multiple search strategies. Data collection and statistical analysis were carried out by the Revman 5.3 software. The Newcastle-Ottawa scale was used to assess the quality of included studies.
  
  
  RESULTS
  A total of 448 studies about HER3 overexpression and GC, and 398 studies about HER4 overexpression and GC were searched. Of these, 5 eligible studies about HER3 including 1016 GC patients and 3 eligible studies about HER4 including 793 GC patients met the inclusion criteria. The results showed that HER3 and HER4 overexpression were significantly associated with depth of tumor invasion (OR = 0.44, 95%CI 0.29-0.67, P = 0.0002 and OR = 0.50, 95%CI 0.38-0.86, P = 0.007) and lymph node metastasis (OR = 0.40, 95%CI 0.20-0.77, P = 0.007 and OR = 0.57, 95%CI 0.38-0.86, P = 0.007), and HER3 overexpression reveals a tendency of later tumor node metastases (TNM) stage (OR = 0.50, 95%CI 0.22-1.15, P = 0.10) and predicts a worse survival time (RR = 0.71, 95%CI 0.61-0.84, P<0.00001), while HER4 overexpression had no correlation with TNM stage (OR = 0.60, 95%CI 0.20-1.78) and survival time (RR = 1.09, 95%CI 0.91-1.30).
  
  
  CONCLUSIONS
  This meta-analysis indicated that HER3 plays an essential role in the clinicopathology and prognosis of GC. However, HER4 may not be an ideal prognostic factor for GC.
authors.affiliation: Anhui Medical University, Hefei, Anhui, 230022, China.
authors.forename: Guo-Dong
authors.identifier: http://orcid.org/0000-0002-4796-6430
authors.initials: GD
authors.lastname: Cao
authors.affiliation: Anhui Medical University, Hefei, Anhui, 230022, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Chen
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.
authors.forename: Mao-Ming
authors.initials: MM
authors.lastname: Xiong
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Chen
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D011379:Prognosis; D020893:Receptor, ErbB-3 / Q000378:metabolism*; D066247:Receptor, ErbB-4 / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; C581292:ERBB3 protein, human; C587689:ERBB4 protein, human; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4